Featured Research

from universities, journals, and other organizations

Antibody-based Therapies Effective At Controlling Malaria

Date:
May 18, 2007
Source:
Public Library of Science
Summary:
Passive immunization through the development of fully human antibodies specific to Plasmodium falciparum may be effective at controlling the disease.

Passive immunization through the development of fully human antibodies specific to Plasmodium falciparum may be effective at controlling the disease, report researchers led by Dr. Richard S. McIntosh from the University of Nottingham in a paper published  in PLoS Pathogens. The researchers developed these novel reagents by antibody repertoire cloning generated from immune Gambian adults.

While it remains unclear if in vitro assays are predictive of functional immunity in humans, due to the lack of suitable animal models, according to this study antimalarial efficacy of human antibodies can be determined using rodent malaria parasites transgenic for P. falciparum antigens in mice and humans. An in vivo mouse model has significant advantage over the use of new world primates, the only other model for human malaria, which are labor-intensive and difficult to reproduce.

These novel human reagents cured mice of an otherwise lethal malaria infection, and protection was crucially dependent on human antibody receptors.

Malaria currently rivals HIV and tuberculosis as the world's most deadly infection, killing two to three million people a year or roughly one person every 30 seconds. The model described in this study provides both a test for therapeutic antibody efficacy prior to clinical trials in humans and an important tool in malaria vaccine development.

This study was supported by a Medical Research Council Career Establishment Award, a European Union Marie Curie Excellence Grant, Antibody Immunotherapy for Malaria, and a ROPA (Realizing Our Potential Award).

Article: McIntosh RS, Shi J, Jennings RM, Chappel JC, de Koning-Ward TF, et al. (2007) The importance of human FcγRI in mediating protection to malaria. PLoS Pathog 3(5): e72. doi:10.1371/journal.ppat.0030072


Story Source:

The above story is based on materials provided by Public Library of Science. Note: Materials may be edited for content and length.


Cite This Page:

Public Library of Science. "Antibody-based Therapies Effective At Controlling Malaria." ScienceDaily. ScienceDaily, 18 May 2007. <www.sciencedaily.com/releases/2007/05/070518062413.htm>.
Public Library of Science. (2007, May 18). Antibody-based Therapies Effective At Controlling Malaria. ScienceDaily. Retrieved October 1, 2014 from www.sciencedaily.com/releases/2007/05/070518062413.htm
Public Library of Science. "Antibody-based Therapies Effective At Controlling Malaria." ScienceDaily. www.sciencedaily.com/releases/2007/05/070518062413.htm (accessed October 1, 2014).

Share This



More Health & Medicine News

Wednesday, October 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Newsy (Sep. 30, 2014) — The CDC says a new case of Ebola has not been reported in Nigeria for more than 21 days, leading to hopes the outbreak might be nearing its end. Video provided by Newsy
Powered by NewsLook.com
UN Ebola Mission Head: Immediate Action Is Crucial

UN Ebola Mission Head: Immediate Action Is Crucial

AFP (Sep. 30, 2014) — The newly appointed head of the United Nations Mission for Ebola Emergency Response (UNMEER), Anthony Banbury, outlines operations to tackle the virus. Duration: 00:39 Video provided by AFP
Powered by NewsLook.com
CDC Confirms First Case of Ebola in US

CDC Confirms First Case of Ebola in US

AP (Sep. 30, 2014) — The CDC has confirmed the first diagnosed case of Ebola in the United States. The patient is being treated at a Dallas hospital after traveling earlier this month from Liberia. (Sept. 30) Video provided by AP
Powered by NewsLook.com
New Breast Cancer Drug Extends Lives In Clinical Trial

New Breast Cancer Drug Extends Lives In Clinical Trial

Newsy (Sep. 30, 2014) — In a clinical trial, breast cancer patients lived an average of 15 months longer when they received new drug Perjeta along with Herceptin. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins